Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Camrelizumab combined with chemotherapy.
- Who it may be relevant to
- Registry conditions: Cervical Cancer, Immunochemotherapy. Basic parameters: 18 years — 70 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Camrelizumab Combined With Chemotherapy for Adjuvant Treatment of Cervical Cancer Patients With Pathologically Confirmed Lymph Node Positivity After Stage Surgery: A Prospective, Single-Arm, Multicenter, Phase II Clinical Trial
Overview
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Interventions
- Drug Camrelizumab combined with chemotherapy
Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery
Primary outcome measures
- 3-year disease-free survival rate [Time frame: from enrollment until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 100 months]
Eligibility criteria
Inclusion criteria
- Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
- Positive PD-L1 expression;
- ECOG score ≤1
Exclusion criteria
- Positive parametrium or surgical margin;
- Incomplete radical surgery;
- Residual target lesions;
- Active autoimmune disease or autoimmune disease requiring systemic treatment;
- Previous treatment with immune checkpoint inhibitors.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Women's Hospital, School of Medicine, Zhejiang University — Hangzhou
Publications
- Chen L, Chen T, Tu N, Dong L, Zhang Y, Wang H, Shen Y. Camrelizumab combined with chemotherapy as postoperative adjuvant therapy after radical surgery for cervical cancer patients with pathologically positive lymph nodes: a prospective multicenter phase II clinical trial. J Gynecol Oncol. 2026 Jul 9. doi: 10.3802/jgo.2027.38.e1. Online ahead of print. PMID 42471761
Identifiers
NCT: NCT07167160 · IRB-20250023